辛伐他汀联合常规治疗对早期糖尿病肾病患者肾功能及肾组织纤维化的影响

doi:10.3969/j.issn.1671-7171.2022.04.020

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1160 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨辛伐他汀联合常规治疗对早期糖尿病肾病(DN)患者肾功能及肾组织纤维化的影响。【方法】本院收治的88例早期DN患者,随机分成观察组(辛伐他汀联合常规血糖控制治疗)与对照组(常规血糖控制治疗),每组44例。比较两组治疗后临床有效率,肾功能指标[血肌酐(SCr)、尿素氮(BUN)、β₂微球蛋白(β₂-MG)、尿白蛋白肌酐比(UACR)、24 h尿蛋白定量],肾纤维化指标[Ⅳ型胶原(Ⅳ-C)、转化生长因子(TGF-β1)、组织基质金属蛋白酶抑制剂-1(TIMP-1)]水平以及用药后不良反应发生情况。【结果】治疗后,观察组总有效率为86.36%(38/44),高于对照组的65.91%(29/44),且差异有统计学意义(P<0.05);两组SCr、BUN、β₂-MG、UACR、24 h尿蛋白量水平较治疗前均降低(P<0.05),且观察组低于对照组(P<0.05);两组Ⅳ-C、TGF-β1、TIMP-1水平较治疗前均降低(P<0.05),且观察组低于对照组(P<0.05)。观察组不良反应总发生率为18.18%(8/44),与对照组的25.00%(11/44)相比较差异无统计学意义(P>0.05)。【结论】辛伐他汀联合常规治疗可提高早期DN患者的治疗有效率,改善肾功能,减缓肾组织纤维化进程,且安全性较高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	殷俊
	邱君思
	邵芳

关键词 ：糖尿病肾病/药物疗法, 羟甲基戊二酰基CoA还原酶抑制剂, 肾功能试验

Abstract：【Objective】To explore the effect of simvastatin combined with conventional treatment on renal function and renal tissue fibrosis in patients with early diabetic nephropathy. 【Methods】A total of 88 patients with early diabetic nephropathy who were admitted to our hospital were selected and randomly divided into the observation group (simvastatin combined with conventional treatment) and the control group (conventional blood glucose control), with 44 cases in each group. The control group received conventional blood glucose control, while the observation group received simvastatin in addition to the conventional blood glucose control group. The clinical effective rate, renal function indexes [serum creatinine (SCr), urea nitrogen (BUN), β₂ - microglobulin (β₂ - MG), urinary albumin-to-creatinine ratio (UACR), and 24 - hour urinary protein quantitation], renal fibrosis indexes [type IV collagen (Ⅳ-C), transforming growth factor (TGF-β1), and tissue matrix metalloproteinase inhibitor-1 (TIMP-1)] were compared between the two groups after treatment, and the adverse drug reactions during treatment were observed as well. 【Results】After treatment, the total effective rate in the observation group was 86.36% (38/44), which was higher than 65.91% (29/44) in the control group, and the difference was statistically significant (P<0.05).After treatment, the levels of SCr, BUN, β₂-MG, UACR and 24h urinary protein in both groups decreased (P<0.05), and the observation group showed even lower level (P<0.05). After treatment, the levels of Ⅳ-C, TGF-β1 and TIMP-1 in the two groups decreased (P<0.05), and the comparison between the two groups showed that the level in the observation group were lower than the control group (P<0.05). The adverse reactions of the observation group was 18.18% (8/44) and of the control group was 25.00% (11/44), which showed no difference (P>0.05).【Conclusion】Simvastatin combined with conventional treatment can improve the clinical efficiency and renal function, while slow down the process of renal fibrosis in patients with early diabetic nephropathy, with high safety.

Key words： Diabetic Nephropathies/DT Hydroxymethylglutaryl-CoA Reductase Inhibitors Kidney Function Tests

收稿日期: 2021-12-22

中图分类号:

R587.24

引用本文:

殷俊, 邱君思, 邵芳. 辛伐他汀联合常规治疗对早期糖尿病肾病患者肾功能及肾组织纤维化的影响[J]. 医学临床研究, 2022, 39(4): 550-552.
YIN Jun, QIU Jun-si, SHAO Fang. Effect of Simvastatin Combined with Conventional Therapy on Renal Function and Renal Fibrosis in Patients with Early Diabetic Nephropathy. JOURNAL OF CLINICAL RESEARCH, 2022, 39(4): 550-552.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.04.020 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I4/550

[1] COLE J B.Genetics of diabetes mellitus and diabetes complications[J].Nat Rev Nephrol,2020, 16(7):377-390.
[2] KOSZEGI S, MOLNAR A, LENART L, et al. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition[J].J Physiol,2019, 597(1):193.
[3] ESMERIJER K, DEKKERS O M, de FIJTER J W, et al. Effect of different types of statins on kidney function decline and proteinuria:a network meta-analysis[J].Sci Rep,2019, 9(1):16632.
[4] 扈瑞春.百令胶囊联合辛伐他汀改善糖尿病肾病微炎症状态临床研究[J].中国药业, 2018, 27(20):73-75.
[5] 中华医学会糖尿病学分会,中国 2 型糖尿病防治指南( 2013年版) [J].中国糖尿病杂志, 2014, 88(8):1227-1245.
[6] MOLITCH M E, DEFRONZO R A, FRANZ M J, et al. American Diabetes Association. Diabetic nephropathy[J].Diabetes Care,2003, 26:S94-S98.
[7] 徐静, 胡晓帆, 黄威, 等. 糖尿病肾病与伴糖尿病的非糖尿病肾脏疾病患者临床病理特征分析[J].中华内科杂志, 2017, 56(12):924-929.
[8] 田琦. 辛伐他汀联合阿司匹林治疗糖尿病肾病患者SOD、MDA水平及肾功能的影响[J].北方药学, 2017, 14(5):144.
[9] 张怡, 沈芳媛, 刘婷, 等. 辛伐他汀联合地尔硫卓治疗糖尿病肾病的疗效及其对蛋白尿的影响[J].中国现代应用药学, 2018, 35(7):1086-1088.
[10] 陈成华, 王丽, 张守来. 缬沙坦联合阿托伐他汀对早期糖尿病肾病患者hs-CRP、LDL-C、SCr水平及肾功能的影响[J].医学临床研究, 2018, 35(1):65-67.
[11] 刘金华, 简庆佳, 邱辉强, 等. CCr、CysC、SCr及BUN指标检测对肾功能不全的价值分析[J].吉林医学, 2017, 38(5):828-829.
[12] 程乐宁. 肾病综合征患者血清β₂-MG,肾功能指标,凝血功能指标测定及其相关性分析[J].四川解剖学杂志, 2019, 27(4):16-17.
[13] 柳河, 吴茂彬. 阿托伐他汀对糖尿病肾病患者肾功能相关血清指标及肾脏纤维化的影响观察[J].中国现代药物应用, 2018, 12(5):1-3.
[14] 李惊东. 阿托伐他汀联合丹红注射液对糖尿病肾病患者肾功能相关指标及肾脏纤维化的影响[J].现代中西医结合杂志, 2018, 27(33):92-94.